Skip Navigation



ToxSci Advance Access published online on July 7, 2005
Toxicological Sciences, doi:10.1093/toxsci/kfi248
This Article
Right arrow Advance Access manuscript (PDF) Freely available
Right arrow All Versions of this Article:
88/1/18    most recent
kfi248v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Jacobs, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jacobs, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published by Oxford University Press 2005.
Received May 4, 2005
Accepted June 24, 2005

Forum

Prediction of 2-year carcinogenicity study results for pharmaceutical products: How are we doing?

Abigail Jacobs 1* *

1 Center for Drug Evaluation and Research, USFDA, 9201 Corporate Blvd, Rm N212, Rockville, MD 20850

* To whom correspondence should be addressed.
Abigail Jacobs, E-mail: Abigail.Jacobs{at}fda.hhs.gov


  Abstract

Some have proposed that 2-year carcinogenicity studies may not be necessary if the material is a direct acting DNA mutagen, induces liver enzymes, causes hyperplasia or toxicity in particular organs, causes cell proliferation, is cytotoxic, causes hormonal perturbations, or if one has QSAR analyses or 'omics information. Safety pharmacology data, pharmacologic activity, metabolism data, and results of 13-week dose ranging studies (with organ weight data, clinical chemistry data, hematologic data, clinical signs and histopathologic findings) were compared with results of 2-year carcinogenicity studies reviewed by the Center for Drug Evaluation and Research (CDER)/FDA. The experience with the ICH genetic toxicology battery and alternative carcinogenicity models was also reviewed. It appears that the information available from short-term studies is not currently sufficient to accurately and reliably predict the outcome of long-term carcinogenicity studies.

*The opinions expressed are those of the author and do not necessarily reflect an official FDA opinion


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Vet PatholHome page
D. Jacobson-Kram
Commentary: Regulatory Toxicology and the Critical Path: Predicting Long-term Outcomes from Short-term Studies
Vet. Pathol., September 1, 2008; 45(5): 707 - 709.
[Full Text] [PDF]

Home page
 Toxicol SciHome page
W. W. Ku, J. Aubrecht, R. J. Mauthe, R. H. Schiestl, and A. J. Fornace Jr
Genetic Toxicity Assessment: Employing the Best Science for Human Safety Evaluation Part VII: Why Not Start with a Single Test: A Transformational Alternative to Genotoxicity Hazard and Risk Assessment
Toxicol. Sci., September 1, 2007; 99(1): 20 - 25.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
M. R. Fielden, R. Brennan, and J. Gollub
A Gene Expression Biomarker Provides Early Prediction and Mechanistic Assessment of Hepatic Tumor Induction by Nongenotoxic Chemicals
Toxicol. Sci., September 1, 2007; 99(1): 90 - 100.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
D. M. Proctor, N. M. Gatto, S. J. Hong, and K. P. Allamneni
Mode-of-Action Framework for Evaluating the Relevance of Rodent Forestomach Tumors in Cancer Risk Assessment
Toxicol. Sci., August 1, 2007; 98(2): 313 - 326.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.